Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Abstract

Currently, a significant proportion of cancer patients do not benefit from programmed cell death-1 (PD-1)-targeted therapy. Overcoming drug resistance remains a challenge. In this study, single-cell RNA sequencing and bulk RNA sequencing data from samples collected before and after anti-PD-1 therapy were analyzed. Cell-cell interaction analyses were performed to determine the differences between pretreatment responders and nonresponders and the relative differences in changes from pretreatment to posttreatment status between responders and nonresponders to ultimately investigate the specific mechanisms underlying response and resistance to anti-PD-1 therapy. Bulk-RNA sequencing data were used to validate our results. Furthermore, we analyzed the evolutionary trajectory of ligands/receptors in specific cell types in responders and nonresponders. Based on pretreatment data from responders and nonresponders, we identified several different cell-cell interactions, like WNT5A-PTPRK, EGFR-AREG, AXL-GAS6 and ACKR3-CXCL12. Furthermore, relative differences in the changes from pretreatment to posttreatment status between responders and nonresponders existed in SELE-PSGL-1, CXCR3-CCL19, CCL4-SLC7A1, CXCL12-CXCR3, EGFR-AREG, THBS1-a3b1 complex, TNF-TNFRSF1A, TNF-FAS and TNFSF10-TNFRSF10D interactions. In trajectory analyses of tumor-specific exhausted CD8 T cells using ligand/receptor genes, we identified a cluster of T cells that presented a distinct pattern of ligand/receptor expression. They highly expressed suppressive genes like HAVCR2 and KLRC1, cytotoxic genes like GZMB and FASLG and the tissue-residence-related gene CCL5. These cells had increased expression of survival-related and tissue-residence-related genes, like heat shock protein genes and the interleukin-7 receptor (IL-7R), CACYBP and IFITM3 genes, after anti-PD-1 therapy. These results reveal the mechanisms underlying anti-PD-1 therapy response and offer abundant clues for potential strategies to improve immunotherapy.

Anhydroicaritin Inhibits EMT in Breast Cancer by Enhancing GPX1 Expression: A Research Based on Sequencing Technologies and Bioinformatics Analysis

“…Programmed cell death protein-1 and programmed cell death protein 1 ligand inhibitors can benefit patients with metastatic BC (Page et al, 2019). However, the immunotherapy of BC remains a major challenge to medical research (Jiang et al, 2021;Tabana et al, 2021). In the present study, we found that GPX1 is related to the immune infiltration of BC.…”

Molecular atlas of the human brain vasculature at the single-cell level

“…Network centrality analysis suggested capillaries (in fetal and control/adult brains) and angiogenic capillaries (in pathological brains) as “senders” and venous ECs (in fetal, adult/control and pathological brains) as major “recipients” of MHC class II signaling and predicted elevated MHC class II signaling (predominantly in angiogenic capillaries) in brain pathologies (Figure 5q-t, Extended Data Figure 35). Notably, MHC class II signaling seems to be mediated mainly by APP and COPA ligands (and to a lesser extent by MIF ) and the CD74 receptor in AV-clusters across development, adulthood and disease (Extended Data Figure 35), and APP/COPA/MIF–CD74 have been described as ligand-receptor pairs between monocyte-derived macrophages and tumor ECs in human lung adenocarcinoma 70 and to be involved in antitumor immune response 83 .…”

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

“…Contrary to what was initially thought, recent data in the literature report anti-tumor reactivity of these exhausted CD8 + T cells and their increase in patients responding to anti-PD-1 therapy, suggesting a key role of these cells in the anti-tumor response. 27 , 28 …”